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considered together. Compared with the widespread appli-
cation of HCV RNA test by quantitative RT-PCR technique,
HCV core antigen detection may be an alternative indicator
in the diagnosis of hepatitis C virus infections and in moni-
toring the status of infectious individuals. However, the ap-
plication and signiﬁcance of HCV core antigen assay and its
correlation with HCV RNA detection are still not well inves-
tigated, especially on the background of HIV coinfection.
Methods: In this study, we analyzed and compared the
serological and virological characteristics of HCV viremia-
positive and viremia-negative patients in a total of 354 HCV
and/or HIV seropositive subjects enrolled from a village of
central China. Besides HCV-related hepatopathic variables
including clinical status, ALT, AST, anti-HCV Abs, as well as
the altered CD4+/CD8+ T cell counts, HCV core antigen and
HCV viral load were also measured.
Results:
1. The 354 participants were divided into 5 groups
(HIV-noninfected CHC (129/354, 36.44%), HIV-infected
CHC (98/354, 27.68%), HIV-1-noninfected SVC (65/354,
18.36%), HIV-infected SVC (44/354, 12.43%), and HIV
infection (18/354, 5.08%) alone) depending on the
existence of anti-HCV antibody, anti-HIV antibody, and
HCV viral load.
2. No signiﬁcant difference of either ALT (X2 = 0.221,
p = 0.638) or AST (X2 = 0.018, p = 0.895) was found
between the HCV mono-infection (HIV-noninfected CHC,
44.96% for ALT and 44.18% for AST) group and the
HCV/HIV coinfection (HIV-infected CHC, 41.84% for ALT
and 45.92% for AST) group. Interestingly, there were
signiﬁcant differences for ALT (X2 = 3.854, p = 0.05) and
AST (X2 = 13.722, p < 0.001) between the HIV-noninfected
SVC (10.78% for ALT and 3.08% for AST) and the HIV-
infected SVC (25.00% for ALT and 27.08% for AST).
3. 96.90% HIV-noninfected CHC patients and 97.96% HIV-
infected CHC patients were reactive to the HCV core
antigen measurement. And for the ﬁrst time, we
reported that serum concentrations of HCV core antigen
were highly correlated with HCV RNA levels in both HCV
mono-infected (r = 0.8083, p < 0.001) and HCV/HIV co-
infected (r = 0.9524, p < 0.001) patients in this study.
4. HCV core antigen concentration was negatively corre-
lated (r = 0.2847, p = 0.0083) with CD4+ T cell counts
less than 1000/ml, and S/CO ratio of anti-HCV antibody
(r = 0.3155, p = 0.0033) was positively correlated with
CD4+ T cell counts in HIV-infected CHC patients with
CD4+ T cell counts, while no correlation was found
between HCV RNA level and CD4+ T cell count.
Conclusions: In total, our ﬁndings demonstrated that there
were distinctive serological and virological characteristics
of serum HCV RNA positive and negative hepatitis C patients
with or without HIV-1 coinfection. Importantly, there was
an excellent correlation between plasma HCV viral load
and the concentration of HCV core protein not only in the
HCV mono-infected population but also in the HCV/HIV-1
coinfected population. The HCV antigen assay detected
the vast majority of HCV RNA positives with or without
HIV infection. Considering HCV, core antigen testing has a
comparable sensitivity to HCV RNA qPCR. HCV core antigen
concentration, but not HCV RNA level, was negatively
correlated with CD4+ T cell counts. Our data suggested that
quantitative detection of plasma HCV core antigen may be a
better indicator of peripheral HCV level than HCV RNA level
when evaluating the association between HCV replication
and host immune status in HCV/HIV coinfected patients.
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Objectives: To elucidate impact of amino acid (aa)
substitutions of interferon sensitivity determining region
(ISDR) of HCV on the outcome of combined pegylated
interferon/ribavirin therapy in the patients with chronic
hepatitits C virus genotype 1b infection in Southern China.
Methods: A total of 44 patients with chronic HCV 1b
infection who received 48 weeks of combination therapy
and 6-month follow up were analyzed retrospectively.
Clinical and laboratory parameters including gender, age,
route of transmission, ALT, AST, quantiﬁcation of HCV RNA
and the substitution number of ISDR were assessed. The
binary logistic regression analysis to identify those that are
independently associated with the early virological response
(EVR), end of treatment virological response (ETVR) and
sustained virological response (SVR) was conducted.
Results: Sequences of ISDR were compared with HCV
J strain.11 of 44 isolates were wild type, 32 were
intermediate type (2 3 aa substitutions) and only 1 was
mutant type (4 or more aa substitutions). The SVR rate
was 43.2% (19/44). The statistical analysis indicated there
was a signiﬁcant correlation between the aa mutation
number (2) in HCV ISDR and SVR/EVR (P= 0.005/P= 0.018);
and the independent variables related to SVR were the
mutation number in ISDR (OR, 17.038; P= 0.011), age group
(40 years) (OR, 12.259; P= 0.011) and AST (OR, 1.021;
P= 0.020).
Conclusions: These results support the hypothesis of aa
substitution at ISDR of HCV genotype 1b could predict SVR.
Although the aa sequence of ISDR is conservative, and the
mutant type of ISDR (4 or more aa substitutions) is rare in
Southern China, it is interesting that the mutation number
of ISDR as a predictor of SVR can decreased from 4 to 2
when using PEG-IFN plus RBV combination therapy.
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Background: The effective standard therapeutic regimen
using PEG-IFN in combination with RBV has led to improved
sustained viral response rates for patients with chronic
hepatitis C (CHC). However, PEG-IFN is very expensive;
most patients cannot afford the treatment in China. The
recombinant IFN-2b is much cheaper and has been proven
to be safe and effective. The low cost allows to treat a
wide range of patients.
Methods: A total of 264 treatment-naïve patients with
CHC received the treatments of recombinant IFNa-2b (5
MIU/qod) and RBV (900mg/d). The efﬁcacy and safety of
the treatment were investigated and inﬂuencing factors
were evaluated.
